Fitness7 months ago
PreludeDx Presents New Data Highlighting Ability of DCISionRT® to Predict Benefit of Radiation Therapy in DCIS Patients, Independent of Endocrine Therapy (ET)
LAGUNA HILLS, Calif., May 30, 2024 /PRNewswire/ — Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, today announced that it will share...
